Actively Recruiting
Phase 1 Randomized Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of SAB01 in Healthy Adults
Led by Santa Ana Bio · Updated on 2026-09-11
88
Participants Needed
2
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SAB01, an investigational bispecific monoclonal antibody targeting mast cells, in a first-in-human Phase 1 clinical trial involving healthy adult participants. The study aims to assess the safety, pharmacokinetics, and pharmacodynamics of single ascending doses of SAB01 administered subcutaneously and intravenously. This randomized, double-blind, placebo-controlled study includes up to 88 participants across planned and optional cohorts monitored by a Safety Review Committee. Participants receive a single dose of SAB01 or placebo via subcutaneous injection or intravenous infusion. The study has 7 planned cohorts for subcutaneous and intravenous administration and up to 4 optional cohorts based on emerging safety and pharmacological data. Dose levels for intravenous administration will not exceed those evaluated by subcutaneous injection. Participants are randomized in a 62 ratio to receive SAB01 or placebo within each cohort. During the study, participants undergo safety and tolerability assessments from Day 1 through Day 113, alongside evaluations of SAB01s plasma pharmacokinetic profile and pharmacodynamic effects. Researchers monitor bioavailability, clearance rates, volume of distribution, half-life, and immunogenicity. Participants are required to comply with all study procedures and are monitored with laboratory tests, physical examinations, and electrocardiograms to ensure health status throughout the study period.
CONDITIONS
Brief Title
Phase 1 Study Involving SAB01 and Healthy Participants
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here